We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults.
- Authors
Schehlein, Emily; Robin, Alan
- Abstract
Glaucoma is a leading cause of irreversible blindness which preferentially affects older individuals. No medications or therapies which are currently in our arsenal actually treat glaucoma itself. We know that intraocular pressure (IOP) is currently the only modifiable risk factor for glaucoma. The primary treatments for glaucoma include medications, laser therapies, and surgical therapies. The Rho kinase inhibitors are the newest class of medications currently on the market and in development for topical IOP-lowering therapy. Studies have shown their ability to lower eye pressure individually and in combination with other medications. Their ability to potentially provide neuroprotective effects for disease modification also gives this class exciting potential for glaucoma treatment.
- Subjects
RISK assessment; GLAUCOMA; INTRAOCULAR pressure; LASER therapy; PHENYLPROPANOLAMINE; BLINDNESS; PHOSPHOTRANSFERASES; DISEASE risk factors; OLD age
- Publication
Drugs & Aging, 2024, Vol 41, Issue 5, p399
- ISSN
1170-229X
- Publication type
Article
- DOI
10.1007/s40266-024-01107-y